{"classes":[{"categories":[{"measurements":[{"comment":"The median and 75th percentile of OS was not reached in either treatment arm. The 25th percentile of OS in the A+CHP arm was 40.9 months as compared with 17.5 months in the CHOP arm.","groupId":"OG000","lowerLimit":"0.0","upperLimit":"86.5","value":"NA"},{"comment":"The median and 75th percentile of OS was not reached in either treatment arm. The 25th percentile of OS in the A+CHP arm was 40.9 months as compared with 17.5 months in the CHOP arm.","groupId":"OG001","lowerLimit":"0.1","upperLimit":"90.0","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"226"}],"units":"Participants"}],"description":"The time from randomization to death due to any cause.","dispersionType":"Full Range","groups":[{"description":"brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone brentuximab vedotin: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles","id":"OG000","title":"A+CHP"},{"description":"cyclophosphamide, doxorubicin, vincristine, and prednisone doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles vincristine: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles","id":"OG001","title":"CHOP"}],"paramType":"MEDIAN","populationDescription":"The Intent-to-Treat (ITT) Analysis Set includes all randomized patients. Patients are included in the treatment group assigned at randomization regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 90 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}